Aclaris Therapeutics, Inc. (ACRS)

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

In setting NEO compensation, we consider compensation for comparable positions in the market, the historical compensation levels of our executives, individual performance as compared to our expectations and objectives, our desire to motivate our employees to achieve short- and long-term results that are in the best interests of our stockholders and a long-term commitment to our company. We do not target a specific competitive position or a specific mix of compensation among base salary, bonus or long-term incentives; however, we do deliver a majority of compensation through long-term incentives.

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

a. Approved under the standard stated in the filing — “Proposal Number ​ ​ ​ Proposal Description ​ ​ ​ Vote Required for Approval ​ Voting Options ​ ​ ​ Effect of Abstentions or Withhold Votes (as Applicable) ​ ​ ​ Effect of Broker Non- Votes 1 ​ Election of Directors ​ Nominees receiving the most "For" votes ​ "For" or "Withold" ​ No effect ​ No effect 2 ​ Advisory vote to approve compensation of our named executive officers ​ "For" votes from holders of a majority of the shares present or represented by proxy at the Annual Meeting and entitled to vote on the matter ​ "For," "Against" or abstain ​ Against ​ No effect 3 ​ Ratification of the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the year ending December 31, 2026 ​ "For" votes from holders of a majority of the shares present or represented by proxy at the Annual Meeting and entitled to vote on the matter ​ "For," "Against" or abstain ​ Against ​ Not applicable (1) (1) This proposal is considered a "routine" matter under NYSE rules.”.

b. Approved under the standard stated in the filing — “Proposal Number Proposal Description Vote Required for Approval ​ Voting Options Effect of Abstentions or Withhold Votes (as Applicable) Effect of Broker Non- Votes 1 ​ Election of Directors ​ Nominees receiving the most "For" votes ​ "For" or "Withold" ​ No effect ​ No effect 2 ​ Advisory vote to approve compensation of our named executive officers ​ "For" votes from holders of a majority of the shares having voting power present or represented by proxy at the Annual Meeting and entitled to vote on the matter ​ "For," "Against" or abstain ​ Against ​ No effect 3 ​ Charter amendment to increase authorized shares of common stock ​ "For" votes from a majority of the votes cast "For" or "Against" the proposal ​ "For," "Against" or abstain ​ No effect ​ Brokers have discretion to vote (1) 4 ​ Approval of 2025 Equity Incentive Plan ​ "For" votes from a majority of the votes cast "For" or "Against" the proposal ​ "For," "Against" or abstain ​ No effect ​ No effect 5 ​ Ratification of the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the year ending December 31, 2025 ​ "For" votes from holders of a majority of the shares having voting power present or represented by proxy at the Annual Meeting and entitled to vote on the matter ​ "For," "Against" or abstain ​ Against ​ Brokers have discretion to vote (1) (1) This proposal is considered a "routine" matter under NYSE rules.”.

c. Approved under the standard stated in the filing — “​ ​ ​ ​ ​ ​ ​ ​ ​ Proposal Number Proposal Description Vote Required for Approval Effect of Abstentions Effect of Broker Non- Votes 1 ​ Election of Directors ​ Nominees receiving the most "For" votes ​ Not applicable ​ No effect 2 ​ Advisory vote to approve compensation of our named executive officers ​ "For" votes from holders of a majority of the shares having voting power present or represented by proxy at the Annual Meeting and entitled to vote on the matter ​ Against ​ No effect 3 ​ Ratification of the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the year ending December 31, 2024 ​ "For" votes from holders of a majority of the shares having voting power present or represented by proxy at the Annual Meeting and entitled to vote on the matter ​ Against ​ Brokers have discretion to vote (1) (1) This proposal is considered a "routine" matter under NYSE rules.”.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.